BRAF and neoplasm: Moreover, combination treatment of tunlametinib with vemurafenib resulted in remarkable tumor inhibition in BRAF mutant melanoma cells, which indicates a strong synergistic effect (Q = 1.51, p < 0.05) (Figure 5C).